Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.62 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | YES1 | P07947 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885458 | 0.89 | MAPK14 (0.79) | MAPK14 | |
| SCHEMBL4882595 | 0.88 | MAPK14 (0.74) | MAPK14RAF1YES1BRAF | |
| SCHEMBL4881859 | 0.87 | MAPK14 (0.75) | MAPK14 | |
| SCHEMBL4885462 | 0.87 | MAPK14 (0.68) | MAPK14RAF1YES1BRAF | |
| SCHEMBL4878902 | 0.87 | MAPK14 (0.68) | MAPK14RAF1YES1BRAF | |
| SCHEMBL4882288 | 0.82 | BRAF (0.65) | MAPK14RAF1YES1BRAF | |
| SCHEMBL4931487 | 0.81 | BRAF (0.59) | MAPK14RAF1YES1BRAF | |
| SCHEMBL4890582 | 0.78 | MAPK14 (0.78) | MAPK14RAF1BRAF | |
| SCHEMBL4877836 | 0.78 | BRAF (0.59) | MAPK14RAF1YES1BRAF | |
| SCHEMBL4884396 | 0.78 | BRAF (0.58) | MAPK14RAF1YES1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275022-A1 | Substituted Quinazolones as Anti-Cancer Agents | BRAF, NRAS, RAF1 | MAPK14 153/4885RAF1 3/4885YES1 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.